Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apomab plus rituximab in relapsed follicular CD20-positive B-cell non-Hodgkin lymphoma after prior rituximab
2007-001666-32Phase 2Terminated
- Sponsor
- Genentech
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Apomab and rituximab in follicular lymphoma (FL) and mature B-cell lymphoma, sponsored by Genentech. Primary endpoint: Objective response. Started Sep 2007; status: terminated.
02
Drugs
Apomabrituximab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2007-001666-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001666-32.